DLCO Explained: Diffusing Capacity in Pulmonary Function Tests

DLCO (Diffusion Capacity of Lungs for Carbon Monoxide) measures the lungs' ability to transfer gas from inhaled air to red blood cells in pulmonary capillaries, involving barriers including the alveolar basement membrane, interstitial space, capillary endothelium, and hemoglobin binding. The test uses a gas mixture of 0.3% CO and 10% helium, with the single breath hold technique being the most common method. DLCO is directly proportional to alveolar volume (VA) and the transfer coefficient (KCO), and must be adjusted for hemoglobin levels, carboxyhemoglobin, and altitude. Clinical interpretation involves analyzing VA, KCO, and DLCO values to differentiate between conditions: isolated reduced DLCO suggests pulmonary hypertension or cardiac failure; reduced VA with normal/high KCO indicates pneumectomy or neuromuscular weakness; reduced VA, DLCO, and KCO points to interstitial lung disease; and normal VA with reduced DLCO suggests pulmonary vascular disease.

DLCO evaluates gas exchange across the alveolar-capillary interface using carbon monoxide, with the 2017 technical standard specifying that patients must be off oxygen for 10 minutes and not smoke on test day, the test requires a deep breath to 90% of vital capacity held for 8-12 seconds, and results must be adjusted for hemoglobin levels (defaulting to 14.6 g/dL for men and 13.4 g/dL for women) and altitude, with repeatability criteria requiring two acceptable maneuvers within 2 units of each other.

DLCO interpretation requires corrections for hemoglobin (7% reduction per gram), lung volume, carboxyhemoglobin, alveolar PCO2, exercise, and body position. DLCO consists of VA (alveolar volume, representing functional lung surface area) and KCO (transfer coefficient, incorporating membrane efficiency, blood availability, and hemoglobin). VA is calculated as TLC minus poorly ventilated volume. Increased DLCO results from elevated KCO: high altitude, asthma exacerbation, polycythemia, severe obesity, bronchus use, and mild left heart failure. Decreased DLCO with normal spirometry indicates vascular problems: anemia, pulmonary hypertension, pulmonary embolism, vasculitis, hepatopulmonary syndrome, or early interstitial lung disease. In restrictive disease, parenchymal disease reduces both VA and KCO, while extraparenchymal disease reduces VA but increases KCO proportionally.

Diffusion capacity is measured using the single-breath method (DLCO) where patients inspire CO mixed with oxygen, hold breath for 10 seconds, then exhale. Corrections are essential: hemoglobin correction normalizes for blood oxygen-carrying capacity, while alveolar volume correction accounts for reduced surface area from conditions like pulmonary resection. DLCO remains normal in chronic bronchitis, neuromuscular diseases, and asthma (though asthma may show elevated DLCO from increased capillary volume). Decreased DLCO indicates emphysema (alveolar destruction) or interstitial lung disease (thickened interstitium).

Barometric pressure decreases with altitude, increasing water vapor percentage and creating larger driving pressure gradients for gas transfer, thereby increasing measured diffusing capacity. At 1,000 meters altitude (~Denver), diffusing capacity increases ~6%; at Mexico City (~2,240 meters), the increase approaches 12%. The GLI reference values were adjusted to sea level to improve consistency across populations. Labs should either adjust measured DLCO to sea level or adjust predicted values to current barometric pressure. Hemoglobin concentration also affects DLCO (increased hemoglobin increases DLCO), and carboxyhemoglobin levels should be measured and reported.

DLCO decreases in conditions affecting alveolar-capillary membrane or pulmonary blood flow: emphysema (alveolar destruction), interstitial lung diseases (fibrosis), pulmonary vascular diseases (thromboembolism, pulmonary hypertension), and anemia (reduced hemoglobin). DLCO increases in conditions with increased pulmonary blood flow: obesity (hyperdynamic circulation), polycythemia (increased hemoglobin), and pulmonary hemorrhage.

DLCO (diffusion capacity measured using carbon monoxide) assesses pulmonary gas exchange function. Carbon monoxide is chosen because it has ~210x higher affinity for hemoglobin than oxygen. Normal DLCO is 25 mL/min/mmHg. Conditions increasing DLCO include polycythemia (excess RBCs) and exercise (increased cardiac output). Conditions decreasing DLCO include anemia (fewer RBCs), emphysema (reduced surface area), and pulmonary fibrosis (increased membrane thickness). Medications like amiodarone, bleomycin, carmustine, cyclophosphamide, and methotrexate can cause pulmonary fibrosis.

Idiopathic pulmonary fibrosis is a restrictive lung disease with reduced FEV1, FVC, DLCO, and PAO2. A critical diagnostic feature is normal FEV1/FVC ratio because both decrease proportionally. Symptoms include dry cough and dyspnea. Laboratory findings include elevated LDH and KL-6. Treatment involves glucocorticoids with pulse therapy for severe cases. Pulmonary hypertension has multiple etiologies including idiopathic, connective tissue disease-associated, and chronic thromboembolism. The distinction between pulmonary artery pressure (before lung) and pulmonary capillary wedge pressure (after lung) is crucial. In pulmonary hypertension, pulmonary artery pressure is elevated while wedge pressure remains normal.

The Diffusion Capacity of Carbon Monoxide (DLCO or TLCO) measures the rate at which carbon monoxide transfers from alveoli to red blood cells, reflecting the efficiency of gas exchange across the alveolar-capillary membrane; this test is based on hemoglobin's high affinity for CO, with DLCO being determined by two factors: blood perfusion to the alveolar capillaries and the surface area available for diffusion. Low DLCO indicates problems with perfusion (such as CHF, pulmonary embolism, anemia, or pulmonary hypertension) or diffusion/surface area (such as pulmonary fibrosis, emphysema, or intrinsic restrictive lung disease), while high DLCO suggests increased perfusion (like left-to-right cardiac shunts, exercise, or severe late-stage asthma). DLCO is particularly valuable for detecting early-stage interstitial lung disease before spirometry changes, assessing prognosis for lung surgery (DLCO <40% predicts poor outcomes), and monitoring drug-induced lung toxicity (especially from bleomycin).

DLCO (diffusing capacity for carbon monoxide) measures gas exchange across the alveolar-capillary membrane. The test involves inhaling 0.3% CO, holding breath for 10 seconds, and exhaling. Normal values are 25 mL/min/mmHg. DLCO is crucial for monitoring chemotherapy patients (like glioblastoma) to assess lung toxicity and titrate drug dosages. It distinguishes emphysema from asthma: both show reduced flow rates, but only emphysema shows reduced DLCO because it destroys lung tissue and capillaries. In restrictive diseases like pulmonary fibrosis, DLCO decreases due to thickened membranes. The test requires hemoglobin correction and quality assurance with 2-3 acceptable tests within 10% of each other.

The Diffusion Capacity of Carbon Monoxide (DLCO or TLCO) measures the rate at which carbon monoxide transfers from alveoli to red blood cells, reflecting the efficiency of gas exchange across the alveolar-capillary membrane; this test is based on hemoglobin's high affinity for CO, with DLCO being determined by two factors: blood perfusion to the alveolar capillaries and the surface area available for diffusion. Low DLCO indicates problems with perfusion (such as CHF, pulmonary embolism, anemia, or pulmonary hypertension) or diffusion/surface area (such as pulmonary fibrosis, emphysema, or intrinsic restrictive lung disease), while high DLCO suggests increased perfusion (like left-to-right cardiac shunts, exercise, or severe late-stage asthma). DLCO is particularly valuable for detecting early-stage interstitial lung disease before spirometry changes, assessing prognosis for lung surgery (DLCO <40% predicts poor outcomes), and monitoring drug-induced lung toxicity (especially from bleomycin).

The DLCO (Diffusing Capacity of the Lung for Carbon Monoxide) test measures the lungs' ability to absorb gas molecules by having patients inhale tracer gas containing carbon monoxide, hold their breath for 10 seconds, and exhale. The test reflects lung volume, surface area, ventilation distribution, alveolar-capillary membrane thickness, and blood flow. It is used to diagnose obstructive diseases (emphysema), restrictive diseases (pulmonary fibrosis), pulmonary vascular diseases, and anemia. The test guides critical decisions for thoracic surgery eligibility, disability determination, and employment. It also monitors drug-induced lung toxicities, such as chemotherapy-related damage in lymphoma patients. The 2017 ATS-ERS guidelines update technical standards, raising vital capacity inflation from 85% to 90%, lowering reproducibility from 3 to 2 units, and simplifying quality control using a three-liter syringe instead of expensive devices. Technicians should proactively contact manufacturers for updated software and not accept results failing new standards.

Carbon monoxide diffusion capacity (DLCO) measures gas exchange across the alveolar-capillary membrane during 10-second breath-hold. Fick's Law explains diffusion: proportional to surface area, pressure difference, and gas solubility; inversely proportional to membrane thickness and square root of molecular weight. Reduced DLCO occurs in restrictive diseases (interstitial lung disease), obstructive diseases (COPD), and vascular diseases (pulmonary hypertension). Increased DLCO occurs in polycythemia. These principles guide interpretation of diffusion testing for early interstitial disease detection, preoperative lung resection assessment, and monitoring disease progression.

Predicted post-operative FEV1 (ppoFEV1) and predicted post-operative DLCO (ppoDLCO) are calculated by multiplying pre-operative values by the fraction of remaining lung tissue. For example, in right upper lobe lobectomy (16/19 lung remaining), ppoFEV1 = 16/19 × pre-op FEV1. Risk stratification uses a stepwise approach: if ppoFEV1/DLCO > 40%, low risk; if <40%, proceed to functional testing (shuttle walk or six-minute walk); if poor function, perform CPET. Patients with VO2 max <15 ml/kg/min are high risk. This systematic approach identifies patients requiring enhanced monitoring after thoracic surgery.